Vaccinex Stock Revenue Per Share
Vaccinex fundamentals help investors to digest information that contributes to Vaccinex's financial success or failures. It also enables traders to predict the movement of Vaccinex Stock. The fundamental analysis module provides a way to measure Vaccinex's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vaccinex stock.
Vaccinex |
Vaccinex Company Revenue Per Share Analysis
Vaccinex's Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.
Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.
CompetitionBased on the latest financial disclosure, Vaccinex has a Revenue Per Share of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Vaccinex Revenue Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vaccinex's direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vaccinex could also be used in its relative valuation, which is a method of valuing Vaccinex by comparing valuation metrics of similar companies.Vaccinex is currently under evaluation in revenue per share category among its peers.
Vaccinex Fundamentals
| Return On Equity | -7.59 | ||||
| Return On Asset | -4.96 | ||||
| Current Valuation | 1.59 M | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 11.50 % | ||||
| Shares Owned By Institutions | 51.30 % | ||||
| Number Of Shares Shorted | 62.11 K | ||||
| Price To Book | 7.34 X | ||||
| Price To Sales | 4.34 X | ||||
| Revenue | 570 K | ||||
| Gross Profit | (13.7 M) | ||||
| EBITDA | (19.75 M) | ||||
| Net Income | (20.25 M) | ||||
| Cash And Equivalents | 11.4 M | ||||
| Cash Per Share | 0.27 X | ||||
| Total Debt | 247 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 8.22 X | ||||
| Book Value Per Share | (2.59) X | ||||
| Cash Flow From Operations | (17.23 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | 7.42 X | ||||
| Target Price | 7.0 | ||||
| Number Of Employees | 37 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 2.86 M | ||||
| Total Asset | 3.63 M | ||||
| Retained Earnings | (339.93 M) | ||||
| Working Capital | (2.57 M) | ||||
| Net Asset | 3.63 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Vaccinex Stock
If you are still planning to invest in Vaccinex check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccinex's history and understand the potential risks before investing.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |